Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation, a company focusing on developing treatments for chronic hepatitis B, will participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference, detailing their progress and hosting individual meetings. Investors can access the live webcast of the conference, where Arbutus will share insights into their clinical-stage pipeline, which includes promising compounds such as imdusiran and an oral PD-L1 inhibitor.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
